他汀类药物使用与疗养院痴呆及非痴呆居民全因死亡率:基于理赔数据的回顾性队列研究
这项回顾性队列研究利用德国一家健康与长期护理保险机构2015年1月至2019年12月的理赔数据,评估他汀使用与疗养院居民全因死亡率的关联。共纳入282,693人,其中96,162人经倾向性评分匹配。痴呆患者中使用他汀者全因死亡率较低(HR 0.80,95%CI 0.78-0.82,p<0.001),非痴呆者同样较低(HR 0.73,95%CI 0.71-0.76,p<0.001)。作者认为他汀治疗可能可在疗养院痴呆居民中继续使用以降低全因死亡风险。
要点
- 疗养院痴呆居民使用他汀与较低全因死亡率相关(HR 0.80,95%CI 0.78-0.82)。
- 疗养院非痴呆居民使用他汀也与较低全因死亡率相关(HR 0.73,95%CI 0.71-0.76)。
- 他汀获益在痴呆与非痴呆居民中一致,作者认为痴呆疗养院居民可继续他汀治疗。
核心结论
- 他汀获益在痴呆与非痴呆疗养院居民中一致,作者认为痴呆疗养院居民可继续他汀治疗以降低全因死亡风险。
研究设计与样本
- 回顾性队列研究,使用德国一家健康与长期护理保险机构2015年1月至2019年12月的理赔数据。
- 共纳入282,693名疗养院居民,其中96,162人经倾向性评分匹配;采用基于倾向性评分的Cox比例风险模型分析。
主要发现
- 总人群68.9%为女性,平均年龄82.91岁(SD ±7.97),平均观察期2.25年(SD ±1.35),记录死亡54,269例。
- 痴呆居民中使用他汀者较未使用者全因死亡率降低(HR 0.80,95%CI 0.78-0.82,p<0.001)。
- 非痴呆居民中使用他汀者较未使用者全因死亡率降低(HR 0.73,95%CI 0.71-0.76,p<0.001)。
- 排除有动脉粥样硬化性心血管疾病(ASCVD)病史者及按年龄、性别、护理等级、痴呆类型分层的亚组分析中,结果相似。
临床怎么用
- 作者认为,疗养院痴呆居民可继续他汀治疗以降低全因死亡风险。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: Little is known about the benefits of statin therapy in older adults with dementia. We aimed to evaluate the role of statin use for all-cause mortality in nursing home residents with and without dementia. METHODS: This retrospective cohort study used claims data collected between January 2015 and December 2019 from a German health and long-term care insurance provider. Propensity score-based Cox proportional hazards models were used to evaluate the association of statin use with all-cause mortality and adjusted for potential confounders in nursing home residents. Subgroup analyses were performed based on the presence or absence of atherosclerotic cardiovascular disease (ASCVD), statin intensity (low, moderate, high), dementia type, age, sex, and level of care required. RESULTS: A total of 282,693 participants were included in the study, of which 96,162 were matched. In total, 68.9% were women, and the mean age was 82.91 years (SD ±7.97). The average observation period was 2.25 years (SD ±1.35), and 54,269 deaths were recorded. Statin use in individuals with dementia resulted in lower all-cause mortality (hazard ratio [HR] 0.80, 95% CI 0.78-0.82, p < 0.001) compared with statin nonusers. Similarly, in individuals without dementia, statin use was associated with lower all-cause mortality (HR 0.73, 95% CI 0.71-0.76, p < 0.001) compared with statin nonusers. Similar findings were observed in subanalyses excluding participants with a history of ASCVD and across subgroups stratified by age, sex, care level required, and dementia type. Statin benefits were consistent among individuals with and without dementia. DISCUSSION: Statin benefits were consistent among individuals with and without dementia. Statin therapy may be continued in nursing home residents with dementia to mitigate the risk of all-cause mortality. CLASSIFICATION OF EVIDENCE: This study provides Class III evidence that nursing home patients receiving statins have a lower mortality rate, whether they have a dementia diagnosis or not.
引用
- O'Sullivan JL, Kohl R, Lech S, et al. Statin Use and All-Cause Mortality in Nursing Home Residents With and Without Dementia: A Retrospective Cohort Study Using Claims Data. Neurology. 2024. PMID: 38412394. doi:10.1212/WNL.0000000000209189
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。